RXi Pharmaceuticals Corp Company Profile (NASDAQ:RXII)

About RXi Pharmaceuticals Corp (NASDAQ:RXII)

RXi Pharmaceuticals Corp logoRXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RXII
  • CUSIP: N/A
  • Web: www.rxipharma.com
Capitalization:
  • Market Cap: $12.39 million
  • Outstanding Shares: 22,127,000
Average Prices:
  • 50 Day Moving Avg: $0.63
  • 200 Day Moving Avg: $0.86
  • 52 Week Range: $0.51 - $3.27
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.98
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $9,000.00
  • Price / Sales: 1,376.79
  • Book Value: $0.37 per share
  • Price / Book: 1.51
Profitability:
  • EBIDTA: ($9,190,000.00)
  • Return on Equity: -155.62%
  • Return on Assets: -120.64%
Debt:
  • Current Ratio: 2.55%
  • Quick Ratio: 2.55%
Misc:
  • Average Volume: 912,257 shs.
  • Beta: 1.24
  • Short Ratio: 1.24
 

Frequently Asked Questions for RXi Pharmaceuticals Corp (NASDAQ:RXII)

What is RXi Pharmaceuticals Corp's stock symbol?

RXi Pharmaceuticals Corp trades on the NASDAQ under the ticker symbol "RXII."

How were RXi Pharmaceuticals Corp's earnings last quarter?

RXi Pharmaceuticals Corp (NASDAQ:RXII) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.08. View RXi Pharmaceuticals Corp's Earnings History.

Where is RXi Pharmaceuticals Corp's stock going? Where will RXi Pharmaceuticals Corp's stock price be in 2017?

1 equities research analysts have issued twelve-month price objectives for RXi Pharmaceuticals Corp's shares. Their forecasts range from $1.71 to $3.50. On average, they expect RXi Pharmaceuticals Corp's stock price to reach $2.61 in the next twelve months. View Analyst Ratings for RXi Pharmaceuticals Corp.

Who are some of RXi Pharmaceuticals Corp's key competitors?

Who owns RXi Pharmaceuticals Corp stock?

RXi Pharmaceuticals Corp's stock is owned by many different of institutional and retail investors. Top institutional investors include BLACKROCK INC. (1.90%). View Institutional Ownership Trends for RXi Pharmaceuticals Corp.

How do I buy RXi Pharmaceuticals Corp stock?

Shares of RXi Pharmaceuticals Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of RXi Pharmaceuticals Corp stock cost?

One share of RXi Pharmaceuticals Corp stock can currently be purchased for approximately $0.56.

Analyst Ratings

Consensus Ratings for RXi Pharmaceuticals Corp (NASDAQ:RXII) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.61 (365.18% upside)

Analysts' Ratings History for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2016S&P Equity ResearchLower Price Target$2.35 -> $1.71N/AView Rating Details
6/7/2016HC WainwrightInitiated CoverageBuy$3.50N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Earnings by Quarter for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Earnings History by Quarter for RXi Pharmaceuticals Corp (NASDAQ:RXII)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.20)($0.12)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.23)($0.60)ViewN/AView Earnings Details
11/10/2016Q316($0.34)($0.34)ViewN/AView Earnings Details
8/11/2016Q216($0.36)($0.34)$0.01 millionViewListenView Earnings Details
5/13/2016Q116($0.45)($0.34)$34.00 million$10.00 millionViewListenView Earnings Details
3/30/2016Q415($0.05)($0.04)ViewListenView Earnings Details
11/12/2015Q315($0.04)($0.04)ViewListenView Earnings Details
8/12/2015Q215($0.09)($0.05)$0.02 millionViewListenView Earnings Details
5/13/2015Q115($0.10)($0.13)$0.02 million$0.03 millionViewListenView Earnings Details
3/30/2015Q414($0.14)($0.13)$0.02 million$0.01 millionViewN/AView Earnings Details
11/13/2014Q314($0.22)($0.17)$0.02 millionViewN/AView Earnings Details
8/14/2014Q214($0.25)($0.23)$0.01 millionViewN/AView Earnings Details
5/14/2014Q114($0.31)($0.32)$0.08 million$0.03 millionViewN/AView Earnings Details
3/28/2014($0.31)$0.84ViewN/AView Earnings Details
11/14/2012Q312($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for RXi Pharmaceuticals Corp (NASDAQ:RXII)
2017 EPS Consensus Estimate: ($0.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.17)($0.17)($0.17)
Q4 20171($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RXi Pharmaceuticals Corp (NASDAQ:RXII)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Insider Ownership Percentage: 4.16%
Institutional Ownership Percentage: 7.42%
Insider Trades by Quarter for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Institutional Ownership by Quarter for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Insider Trades by Quarter for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/26/2017Geert CauwenberghCEOBuy10,000$0.65$6,500.00View SEC Filing  
3/17/2017Geert CauwenberghCEOBuy10,000$0.77$7,700.00View SEC Filing  
2/17/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
2/8/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
1/25/2017Geert CauwenberghCEOBuy10,000$0.70$7,000.00View SEC Filing  
1/19/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
4/2/2015Geert CauwenberghCEOBuy5,000$0.72$3,600.00View SEC Filing  
2/17/2015Geert CauwenberghCEOBuy4,000$1.17$4,680.00View SEC Filing  
2/10/2015Geert CauwenberghCEOBuy2,000$1.24$2,480.00View SEC Filing  
1/22/2015Robert J BittermanDirectorBuy5,000$1.20$6,000.00View SEC Filing  
1/20/2015Geert CauwenberghCEOBuy10,000$1.03$10,300.00View SEC Filing  
12/30/2014Geert CauwenberghCEOBuy2,500$1.59$3,975.00View SEC Filing  
10/13/2014Geert CauwenberghCEOBuy3,000$1.68$5,040.00View SEC Filing  
9/19/2014Geert CauwenberghCEOBuy4,500$2.20$9,900.00View SEC Filing  
9/16/2014Geert CauwenberghCEOBuy5,000$2.08$10,400.00View SEC Filing  
9/15/2014Geert CauwenberghCEOBuy10,000$2.18$21,800.00View SEC Filing  
7/15/2014Geert CauwenberghCEOBuy1,000$2.50$2,500.00View SEC Filing  
7/9/2014Geert CauwenberghCEOBuy1,400$2.57$3,598.00View SEC Filing  
7/2/2014Geert CauwenberghCEOBuy2,000$2.86$5,720.00View SEC Filing  
6/19/2014Geert CauwenberghCEOBuy2,000$2.98$5,960.00View SEC Filing  
6/9/2014Geert CauwenberghCEOBuy1,000$3.05$3,050.00View SEC Filing  
6/4/2014Geert CauwenberghCEOBuy2,000$2.94$5,880.00View SEC Filing  
10/31/2013Geert CauwenberghCEOBuy1,000$3.17$3,170.00View SEC Filing  
10/23/2013Geert CauwenberghCEOBuy1,000$3.34$3,340.00View SEC Filing  
10/9/2013Geert CauwenberghCEOBuy1,000$3.15$3,150.00View SEC Filing  
8/29/2013Curtis LockshinDirectorBuy1,000$3.70$3,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Latest Headlines for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Source:
DateHeadline
americanbankingnews.com logo RXi Pharmaceuticals Corp (RXII) Receives Average Rating of "" from Brokerages
www.americanbankingnews.com - May 25 at 12:22 AM
bizjournals.com logoHow These Biotech Stocks are Faring? -- Idera Pharma, BioTime, RXi Pharma, and Tenax Therapeutics
www.bizjournals.com - May 24 at 9:41 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum
finance.yahoo.com - May 23 at 9:32 AM
finance.yahoo.com logoPCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology
finance.yahoo.com - May 22 at 9:12 AM
americanbankingnews.com logo-$0.20 EPS Expected for RXi Pharmaceuticals Corp (RXII) This Quarter
www.americanbankingnews.com - May 15 at 2:22 PM
reuters.com logoBRIEF-Rxi Pharmaceuticals posts Q1 loss per share $0.27
www.reuters.com - May 12 at 11:02 PM
finance.yahoo.com logoEdited Transcript of RXII earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 11:02 PM
americanbankingnews.com logoRXi Pharmaceuticals Corp (RXII) Releases Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 12 at 12:38 PM
seekingalpha.com logoRXi Pharmaceuticals' (RXII) CEO Geert Cauwenbergh on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 1:05 AM
rttnews.com logoEARNINGS SUMMARY: Details of RXi Pharmaceuticals Corp. Q1 Earnings Report
www.rttnews.com - May 11 at 8:08 AM
finance.yahoo.com logoRXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - May 11 at 8:08 AM
americanbankingnews.com logoZacks: RXi Pharmaceuticals Corp (RXII) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - May 8 at 11:26 AM
finance.yahoo.com logoRXi Pharmaceuticals to Webcast First Quarter 2017 Financial Results on Thursday, May 11, 2017 - Yahoo Finance
finance.yahoo.com - May 4 at 7:57 PM
finance.yahoo.com logoRXi Pharmaceuticals to Webcast First Quarter 2017 Financial Results on Thursday, May 11, 2017
finance.yahoo.com - May 4 at 8:57 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting
finance.yahoo.com - May 2 at 9:40 AM
americanbankingnews.com logoSomewhat Critical News Coverage Somewhat Likely to Impact RXi Pharmaceuticals Corp (RXII) Stock Price
www.americanbankingnews.com - April 28 at 2:42 PM
finance.yahoo.com logoRXi Pharmaceuticals to Present at 19th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference - Yahoo Finance
finance.yahoo.com - April 26 at 5:33 PM
americanbankingnews.com logoRXi Pharmaceuticals Corp (RXII) Given Daily Media Impact Rating of 0.09
www.americanbankingnews.com - April 25 at 7:12 PM
finance.yahoo.com logoRXi Pharmaceuticals to Present at 19th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
finance.yahoo.com - April 25 at 10:04 AM
americanbankingnews.com logo Analysts Expect RXi Pharmaceuticals Corp (RXII) Will Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - April 24 at 10:26 PM
americanbankingnews.com logo RXi Pharmaceuticals Corp (RXII) Given $8.00 Average Target Price by Brokerages
www.americanbankingnews.com - April 21 at 7:57 AM
streetinsider.com logoRXI Pharma (RXII) Names Gerrit Dispersyn as CDO - StreetInsider.com
www.streetinsider.com - April 20 at 8:26 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society for Investigative Dermatology 76th Annual Meeting
finance.yahoo.com - April 20 at 8:26 AM
streetinsider.com logoRXI Pharma (RXII) Names Gerrit Dispersyn as CDO
www.streetinsider.com - April 18 at 9:22 AM
finance.yahoo.com logoRXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes
finance.yahoo.com - April 18 at 9:22 AM
americanbankingnews.com logoRXi Pharmaceuticals Corp (RXII) Earning Somewhat Negative News Coverage, Report Shows
www.americanbankingnews.com - April 16 at 11:03 AM
finance.yahoo.com logoThe Life Sciences Report Examines RXi Pharmaceuticals Receiving Japanese Patent for RNAi Platform - Yahoo Finance
finance.yahoo.com - April 15 at 8:22 AM
americanbankingnews.com logoRXi Pharmaceuticals Corp (RXII) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 15 at 7:12 AM
finance.yahoo.com logoThe Life Sciences Report Examines RXi Pharmaceuticals Receiving Japanese Patent for RNAi Platform
finance.yahoo.com - April 13 at 9:58 AM
americanbankingnews.com logoZacks: Analysts Set $8.00 Target Price for RXi Pharmaceuticals Corp (RXII)
www.americanbankingnews.com - April 6 at 5:37 PM
americanbankingnews.com logoRXi Pharmaceuticals Corp (RXII) Issues Earnings Results
www.americanbankingnews.com - March 31 at 10:11 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 31 at 8:03 AM
rttnews.com logoEARNINGS SUMMARY: Details of RXi Pharmaceuticals Corp. Q4 Earnings Report
www.rttnews.com - March 30 at 7:53 PM
finance.yahoo.com logoRXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 30 at 7:53 PM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 7:53 PM
biz.yahoo.com logoQ4 2016 Rxi Pharmaceuticals Corp Earnings Release - After Market Close
biz.yahoo.com - March 30 at 7:53 PM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 30 at 7:53 PM
streetinsider.com logoRXI Pharma (RXII) Announces Patent in Japan for Lead Clinical Candidate RXI-109 - StreetInsider.com
www.streetinsider.com - March 29 at 9:29 PM
americanbankingnews.com logoRXi Pharmaceuticals Corp (RXII) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 29 at 7:08 AM
investopedia.com logoRXi Pharma Derma Drug Gets Japanese Patent (RXII)
www.investopedia.com - March 28 at 7:31 PM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 28 at 7:31 PM
investopedia.com logoRXi Pharma Derma Drug Secures Japanese Patent
www.investopedia.com - March 28 at 7:31 PM
rttnews.com logoRXi Granted Patent In Japan For Lead Clinical Candidate RXI-109
www.rttnews.com - March 28 at 9:31 AM
streetinsider.com logoRXI Pharma (RXII) Announces Patent in Japan for Lead Clinical Candidate RXI-109
www.streetinsider.com - March 28 at 9:31 AM
finance.yahoo.com logoRXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109
finance.yahoo.com - March 28 at 9:31 AM
finance.yahoo.com logo7:06 am RXi Pharma granted a patent from the Japan Patent Office for the composition of matter of sd-rxRNAs targeting connective tissue growth factor for the treatment or prevention of fibrotic disorders, including but not limited to skin f
finance.yahoo.com - March 28 at 9:31 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the 5th Annual Cancer BioPartnering & Investment Forum
finance.yahoo.com - March 22 at 8:35 AM
americanbankingnews.com logo RXi Pharmaceuticals Corp (RXII) Given Consensus Recommendation of "" by Brokerages
www.americanbankingnews.com - March 21 at 11:52 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the 2nd Annual Oligonucleotide and Peptide Therapeutics Conference
finance.yahoo.com - March 21 at 10:27 AM
finance.yahoo.com logoRXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2016 Financial Results on Thursday, March 30, 2017
finance.yahoo.com - March 16 at 8:04 AM

Social

Chart

RXi Pharmaceuticals Corp (RXII) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff